Please try another search
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Alan D. D'Andrea | - | - | Chairman of Scientific Advisory Board |
Terry J. Rosen | 63 | 2016 | Independent Chairman of the Board |
Trey Ideker | - | 2016 | Member of Scientific Advisory Board |
Wendy L. Yarno | 68 | 2019 | Independent Director |
William R. Sellers | 62 | 2019 | Member of Scientific Advisory Board |
Elizabeth Swisher | - | 2016 | Member of Scientific Advisory Board |
Malcolm Garret Hampton | 57 | 2020 | Independent Director |
Jeffrey L. Stein | 68 | 2015 | Independent Director |
Scott W. Morrison | 65 | 2018 | Independent Director |
Frank P. McCormick | 73 | 2019 | Chair of Scientific Advisory Board |
Susan L. Kelley | 68 | 2021 | Independent Director |
Catherine J. Mackey | 68 | 2022 | Independent Director |
Karlene Cimprich | - | 2022 | Member of Scientific Advisory Board |
Kornelia Polyak | - | 2022 | Member of Scientific Advisory Board |
Yujiro S. Hata | 50 | 2015 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review